These 2 Stocks Are Ridiculously Cheap

Bargain-hunters take note: Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) went “from the outhouse to the penthouse, and back to the outhouse again.” Meanwhile, the second stock on this list is a case of “the baby being thrown out with the bathwater.” Don’t miss out.

| More on:
The Motley Fool
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Bargain-hunters: take note.

No, we aren’t going to be looking through an abandoned storage unit for someone’s discarded jewelry or an antique piece of furniture.

We’re looking at two ridiculously cheap stocks that can help make us a lot of money.

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX)

This one’s a story of “from the outhouse to the penthouse, and back to the outhouse again.”

At the start of 2010, VRX shares traded in the low teens. That was, until management went on a buying spree of historical proportions to acquire drug company after drug company, racking up an immense debt load and shunning investments in research and development along the way.

What resulted was a bloated company with too much debt and not enough drugs in the pipeline. That got everyone jittery, and the selling began. Shares fell from their highs of $280 per share all the way to below $10 in just under 18 months.

Is there a chance the market overreacted at some point along the way?

The stock is trading at just 2.5 times cash flow from operations, so perhaps maybe a little.

Let’s break that figure down for a moment.

That the company trades at a mere 2.5 times cash flow tells us that management could shut down capital expenditures (which aren’t a part of the company’s current business strategy anyway) and pay itself off, completely, in 2.5 years.

That’s not a bad return on your investment, right?

Cenovus Energy Inc. (TSX:CVE)(NYSE:CVE)

Cenovus is more along the lines of “the baby just got thrown out with the bathwater.”

You see, Cenovus shares, it would seem, have just gotten caught up in the wake of broader selling across the energy sector.

Now, as the price of WTI crude has fallen by 20% this year, that would make a little sense — except that Cenovus is unique in that it operates as an integrated producer.

So, while Cenovus is busily extracting crude from the ground, like so many other oil and gas production companies, it is also involved in the refining of that crude into products like diesel and gasoline and selling those refined products to end markets.

This means that when the price of crude is low, like it is today, Cenovus receives less money for the oil, but, at the same time, the lower oil price acts as a lower input cost for the refining side of things. It’s a little like a built-in hedge that limits the company’s exposure to volatile swings in the price of oil.

Perhaps some of this is lost on the market.

The good news for investors is recent selling in CVE shares has created a nice buying opportunity for those who have been patiently waiting on the sidelines.

Today, CVE shares are available at one times “clean” book value after accounting for goodwill and intangible assets.

It’s another opportunity that is very, very difficult to pass up on.

Don’t let these two bargain-basement stocks run away on you before its too late.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Jason Phillips has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Dividend Stocks

growing plant shoots on stacked coins
Dividend Stocks

5 Dividend Stocks to Buy With Yields Upwards of 5%

These five companies all earn tonnes of cash flow, making them some of the best long-term dividend stocks you can…

Read more »

funds, money, nest egg
Dividend Stocks

TFSA Investors: 3 Stocks to Start Building an Influx of Passive Income

A TFSA is the ideal registered account for passive income, as it doesn't weigh down your tax bill, and any…

Read more »

A red umbrella stands higher than a crowd of black umbrellas.
Dividend Stocks

3 of the Safest Dividend Stocks in Canada

Royal Bank of Canada stock is one of the safest TSX dividend stocks to buy. So is CT REIT and…

Read more »

Growing plant shoots on coins
Dividend Stocks

1 of the Top Canadian Growth Stocks to Buy in February 2023

Many top Canadian growth stocks represent strong underlying businesses, healthy financials, and organic growth opportunities.

Read more »

stock research, analyze data
Dividend Stocks

Wherever the Market Goes, I’m Buying These 3 TSX Stocks

Here are three TSX stocks that could outperform irrespective of the market direction.

Read more »

woman data analyze
Dividend Stocks

1 Oversold Dividend Stock (Yielding 6.5%) to Buy This Month

Here's why SmartCentres REIT (TSX:SRU.UN) is one top dividend stock that long-term investors should consider in this current market.

Read more »

IMAGE OF A NOTEBOOK WITH TFSA WRITTEN ON IT
Dividend Stocks

Better TFSA Buy: Enbridge Stock or Bank of Nova Scotia

Enbridge and Bank of Nova Scotia offer high yields for TFSA investors seeking passive income. Is one stock now undervalued?

Read more »

Golden crown on a red velvet background
Dividend Stocks

2 Top Stocks Just Became Canadian Dividend Aristocrats

These two top Canadian Dividend Aristocrats stocks are reliable companies with impressive long-term growth potential.

Read more »